Stock Research for CYCC

CYCC

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

CYCC Stock Chart & Research Data

The CYCC chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CYCC chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CYCC Due diligence Resources & Stock Charts

The CYCC stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CYCC Detailed Price Forecast - CNN Money CNN View CYCC Detailed Summary - Google Finance
Yahoo View CYCC Detailed Summary - Yahoo! Finance Zacks View CYCC Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View CYCC Trends & Analysis - Trade-Ideas Barrons View CYCC Major Holders - Barrons
NASDAQ View CYCC Call Transcripts - NASDAQ Seeking View CYCC Breaking News & Analysis - Seeking Alpha
Spotlight View CYCC Annual Report - CompanySpotlight.com OTC Report View CYCC OTC Short Report - OTCShortReport.com
TradeKing View CYCC Fundamentals - TradeKing Charts View CYCC SEC Filings - Bar Chart
WSJ View Historical Prices for CYCC - The WSJ Morningstar View Performance/Total Return for CYCC - Morningstar
MarketWatch View the Analyst Estimates for CYCC - MarketWatch CNBC View the Earnings History for CYCC - CNBC
StockMarketWatch View the CYCC Earnings - StockMarketWatch MacroAxis View CYCC Buy or Sell Recommendations - MacroAxis
Bullish View the CYCC Bullish Patterns - American Bulls Short Pains View CYCC Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View CYCC Stock Mentions - StockTwits PennyStocks View CYCC Stock Mentions - PennyStockTweets
Twitter View CYCC Stock Mentions - Twitter Invest Hub View CYCC Investment Forum News - Investor Hub
Yahoo View CYCC Stock Mentions - Yahoo! Message Board Seeking Alpha View CYCC Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for CYCC - SECform4.com Insider Cow View Insider Transactions for CYCC - Insider Cow
CNBC View CYCC Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CYCC - OTC Markets
Yahoo View Insider Transactions for CYCC - Yahoo! Finance NASDAQ View Institutional Holdings for CYCC - NASDAQ


Stock Charts

FinViz View CYCC Stock Insight & Charts - FinViz.com StockCharts View CYCC Investment Charts - StockCharts.com
BarChart View CYCC Stock Overview & Charts - BarChart Trading View View CYCC User Generated Charts - Trading View




Latest Financial News for CYCC


Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
Posted on Monday April 01, 2024

- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that new clinical, pharmacokinetic (PK) and pharmacodynamic (PD) data fr


Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript
Posted on Wednesday March 20, 2024

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript March 19, 2024 Cyclacel Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-6.23, expectations were $-6.35. CYCC isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to the […]


Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Posted on Tuesday March 19, 2024

– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – – Oral Plogosertib Preclinical Data Support Precision Medicine Strategy in ARID1A- and SMARCA-Mutated Cancers – – Management to Host Conference Call at 4:30 pm ET Today – BERKELEY HEIGHTS, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company dev


Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
Posted on Wednesday March 13, 2024

BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2023 financial results on Tuesday, March 19, 2024. The Company will host a conference call at 4:30pm ET on the same day. Conference call information: Participant Toll-Free Number: 800-579-2543 Primary Participant Dire


Stock Market & Investing Books

Enter a stock symbol to view the stock details.